Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)
China · Delayed Price · Currency is CNY 5.10
+0.35 (7.37%)
Sep 30, 2026, 3:04 PM CST
SHE:002581 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 298.07 | 274.81 | 360.41 | 429.79 | 357.08 | 402.71 |
Revenue Growth | 35.24% | -23.75% | -16.14% | 20.36% | -11.33% | 45.47% |
Gross Profit Gross Profit Growth | 82.25 | 121.89 | 272.74 | 336.5 | 280.44 | 316.88 |
Operating Income Operating Income Growth | -191.86 | -189.51 | -90.86 | -155.81 | -175.57 | -203.95 |
Net Income Net Income Growth | -144.45 | -116.28 | -137.31 | -332.46 | -14.68 | 271 |
Earnings Per Share EPS Growth | -0.22 | -0.18 | -0.21 | -0.50 | -0.02 | 0.41 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 |
|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Biopharmaceutical Biopharmaceutical Growth | 138.24 | 188.68 | 360.41 |
Traditional Chinese Medicine Decoction Pieces Processing Traditional Chinese Medicine Decoction Pieces Processing Growth | - | 83.07 | - |
Pharmaceutical Distribution Pharmaceutical Distribution Growth | - | 2.99 | - |
Unallocated Other Unallocated Other Growth | - | 0.07 | - |
Total Total Growth | 298.07 | 274.81 | 360.41 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 242.84 | 220.27 | 506.4 | 151.91 | 183.8 | 187.8 |
Total Debt Total Debt Growth | 58.15 | 61.43 | 2.94 | 14.55 | 165.35 | 177.16 |
Net Cash (Debt) Net Cash Growth | 184.68 | 158.84 | 503.47 | 137.36 | 18.45 | 10.64 |
Net Cash Growth | -59.15% | -68.45% | 266.52% | 644.38% | 73.50% | -90.91% |
Net Cash Per Share Net Cash Per Share Growth | 0.28 | 0.24 | 0.76 | 0.21 | 0.03 | 0.02 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | -180.87 | -253.73 | -6.55 | -36.51 | -54.49 | -46.02 |
Capital Expenditures CapEx Growth | -166.45 | -179.7 | -9.01 | -4.32 | -31.46 | -60.85 |
Free Cash Flow Free Cash Flow Growth | -347.31 | -433.43 | -15.56 | -40.82 | -85.95 | -106.86 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 27.59% | 44.36% | 75.67% | 78.30% | 78.54% | 78.69% |
Operating Margin | -64.37% | -68.96% | -25.21% | -36.25% | -49.17% | -50.64% |
Pretax Margin | -62.21% | -63.87% | -40.56% | -72.88% | 3.56% | 69.18% |
Profit Margin | -48.46% | -42.31% | -38.10% | -77.35% | -4.11% | 67.29% |
FCF Margin | -116.52% | -157.72% | -4.32% | -9.50% | -24.07% | -26.53% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | - | 51.98 |
PS Ratio | 11.29 | 18.01 | 19.48 | 22.41 | 29.10 | 34.98 |